Brenda Burton
Charles River Laboratories (United Kingdom)(GB)
Publications by Year
Research Areas
Retinoids in leukemia and cellular processes, Computational Drug Discovery Methods, Drug Transport and Resistance Mechanisms, Melanoma and MAPK Pathways, Receptor Mechanisms and Signaling
Most-Cited Works
- → The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy(2001)90 cited
- → Minor Structural Change to Tertiary Sulfonamide RORc Ligands Led to Opposite Mechanisms of Action(2014)82 cited
- → Structure-based design of substituted hexafluoroisopropanol-arylsulfonamides as modulators of RORc(2013)62 cited
- → Reduction in lipophilicity improved the solubility, plasma–protein binding, and permeability of tertiary sulfonamide RORc inverse agonists(2014)49 cited
- → Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479(2014)38 cited
- → Discovery of Novel Allosteric Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors Possessing Bidentate Ser212 Interactions(2012)37 cited
- → Identification of tertiary sulfonamides as RORc inverse agonists(2014)27 cited
- → Mitigation of Acetylcholine Esterase Activity in the 1,7-Diazacarbazole Series of Inhibitors of Checkpoint Kinase 1(2015)18 cited
- → Discovery of LRRK2 inhibitors by using an ensemble of virtual screening methods(2017)16 cited
- → 5-Aminopyrimidin-2-ylnitriles as Cathepsin K inhibitors(2009)13 cited